Chlamydia trachomatis (CT) is the leading cause of preventable blindness (trachoma) and sexually transmitted diseases (STD) worldwide. While much has been learned about human chlamydial infections in the last decades, we are still lacking a complete understanding of the pathogenesis of CT diseases, and do not have an appropriate tool for precisely typing CT strains both for molecular epidemiologic and basic research studies. The major outer membrane protein (MOMP) of CT is an immunodominant protein and the primary target for serotyping, and hence strain typing along with the ompA gene, which encodes MOMP. Yet, MOMP does not fully reflect the phylogeny of the organism or distinguish strains by biologic or phenotypic properties. Other genes/proteins that may contribute to phylogeny, or these properties include the inter-genic region (IGR), polymorphic membrane proteins (Pmps), cytotoxin genes in the replication termination region (RTR) or """"""""plasticity zone"""""""", partial tryptophan operon proteins (TrpB/A), Type III secretion system proteins, chlamydial protease- or proteasome-like activity factor (CPAF), and the porin protein, PorB. Further, the majority of research on CT has used laboratory-adapted strains that may not reflect current clinical isolates that are responsible for the myriad of CT diseases described today. Our goal is to advance the genetic discovery initiated by the CT genome sequences of serovars D and L2 and other genomes of the family Chlamydiaceae by providing genome sequences of six of the 13 remaining reference serovars along with genomes of recent clinical isolates to advance our understanding of CT tissue tropism, virulence, disease pathogenesis, and evolution. Within the context of our Specific Aims, we will develop and make publicly available the data and research tools described: 1) Sequence six genomes of the remaining 13 reference serovars of CT and four genomes of selected recent clinical isolates (see #2), and develop a multi-locus sequence typing (MLST) scheme for global epidemiologic studies; MLST screening of the seven remaining reference serovars and -500 isolates from CT STD and trachoma populations worldwide will fine-tune the MLST and identify unique clinical isolates for additional genome sequencing; 2) Develop a Chlamydia GeneChip for rapid, robust genotyping of CT based on genome data and MLST findings; and 3) Develop a strain identification database to address specific research questions related to unraveling the association between genetic determinants and tissue tropism, virulence, and disease outcome in addition to the evolution of the organism and how new strain types might evolve over time. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI059647-03S1
Application #
7236941
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Hiltke, Thomas J
Project Start
2004-04-01
Project End
2009-03-31
Budget Start
2006-06-01
Budget End
2007-03-31
Support Year
3
Fiscal Year
2006
Total Cost
$104,640
Indirect Cost
Name
Children's Hospital & Res Ctr at Oakland
Department
Type
DUNS #
076536184
City
Oakland
State
CA
Country
United States
Zip Code
94609
Joseph, Sandeep J; Didelot, Xavier; Rothschild, James et al. (2012) Population genomics of Chlamydia trachomatis: insights on drift, selection, recombination, and population structure. Mol Biol Evol 29:3933-46
Srinivasan, Tara; Bruno, William J; Wan, Raymond et al. (2012) In vitro recombinants of antibiotic-resistant Chlamydia trachomatis strains have statistically more breakpoints than clinical recombinants for the same sequenced loci and exhibit selection at unexpected loci. J Bacteriol 194:617-26
Joseph, Sandeep J; Didelot, Xavier; Gandhi, Khanjan et al. (2011) Interplay of recombination and selection in the genomes of Chlamydia trachomatis. Biol Direct 6:28
Somboonna, Naraporn; Wan, Raymond; Ojcius, David M et al. (2011) Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages. MBio 2:e00045-11
Skwor, Troy; Kandel, Ram Prasad; Basravi, Sunniya et al. (2010) Characterization of humoral immune responses to chlamydial HSP60, CPAF, and CT795 in inflammatory and severe trachoma. Invest Ophthalmol Vis Sci 51:5128-36
Dean, D (2009) Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis. Drugs Today (Barc) 45 Suppl B:25-31
Dean, Deborah; Bruno, William J; Wan, Raymond et al. (2009) Predicting phenotype and emerging strains among Chlamydia trachomatis infections. Emerg Infect Dis 15:1385-94
Somboonna, Naraporn; Mead, Sally; Liu, Jessica et al. (2008) Discovering and differentiating new and emerging clonal populations of Chlamydia trachomatis with a novel shotgun cell culture harvest assay. Emerg Infect Dis 14:445-53
Dean, Deborah; Kandel, Ram P; Adhikari, Him K et al. (2008) Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and control. PLoS Med 5:e14
Atik, Berna; Skwor, Troy A; Kandel, Ram Prasad et al. (2008) Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS One 3:e3600

Showing the most recent 10 out of 14 publications